Skip to main content
. 2018 May 29;9(41):26353–26369. doi: 10.18632/oncotarget.25293

Figure 6. LDC526 treatment depletes peripheral blood CLL cells.

Figure 6

(A) Representative flow cytometry plots of peripheral blood leukocytes (experimental scheme outlined in Figure 5A) stained with antibodies against CD5, CD19 and CD3 defining TCL1 CLL cells (CD5+CD19+), T cells (CD5+CD19-CD3+) and non-malignant B cells (CD5-CD19+), red arrows. By previous gating doublets (FSC-A vs. FSC-W) and dead cells (DAPI+) were excluded from the analysis. (B) Longitudinal quantification of circulating CLL cells. (C) Percent of CLL numbers relating to baseline values (day -5). (D) Longitudinal quantification of circulating T cells. (E) Percent of T cell numbers relating to baseline values (day -5). (F) Longitudinal quantification of non-malignant blood B cells. (G) Percent of non-malignant B cell numbers relating to baseline values (day -5). * p<0.05; ** p<0.01.